Furthermore, alectinib demonstrated superior CNS activity versus that of crizotinib in ALK-positive NSCLC patients6, and it has been approved for the first-line treatment of ALK-positive NSCLC patients. The gene discussed is ALK; the disease is non-small cell lung carcinoma.